- Home
- WOOF vs ABUS Comparison
WOOF vs ABUS Comparison
Compare WOOF & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | ABUS |
|---|---|---|
| Founded | 1965 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 888.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | WOOF | ABUS |
|---|---|---|
| Price | $2.62 | $3.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $3.83 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.8M |
| Earning Date | 03-25-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,998,469,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $0.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $2.28 | $2.71 |
| 52 Week High | $4.51 | $5.10 |
Technical Indicators
Market Signals| Indicator | WOOF | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 34.33 |
| Support Level | $2.48 | $3.62 |
| Resistance Level | $3.02 | $4.60 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 6.48 | 20.00 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.